Qualitative or quantitative defects of beta-sarcoglycan

Qualitative or quantitative defects of beta-sarcoglycan (also known as beta-sarcoglycanopathy or Limb-Girdle Muscular Dystrophy type R4, formerly LGMD2E) is a rare inherited muscular dystrophy caused by mutations in the SGCB gene, which encodes the beta-sarcoglycan protein. Beta-sarcoglycan is a critical component of the dystrophin-associated glycoprotein complex (DGC), which provides structural stability to muscle cell membranes during contraction. When beta-sarcoglycan is absent, reduced, or dysfunctional, the muscle fiber membrane becomes fragile and susceptible to contraction-induced damage, leading to progressive muscle degeneration. The disease primarily affects the skeletal muscular system, with progressive weakness and wasting of the proximal limb-girdle muscles — particularly the hip and shoulder girdle muscles. Onset is typically in childhood, often before age 10, and patients may present with difficulty running, climbing stairs, or rising from the floor. The condition can progress to loss of ambulation, and cardiac involvement including dilated cardiomyopathy has been reported in some patients. Elevated serum creatine kinase (CK) levels, often markedly elevated (10–100 times normal), are a hallmark laboratory finding. Respiratory insufficiency may develop as the disease progresses. There is currently no cure for beta-sarcoglycanopathy. Management is supportive and multidisciplinary, including physical therapy to maintain mobility, orthopedic interventions for contractures and scoliosis, cardiac monitoring and treatment of cardiomyopathy, and respiratory support as needed. Corticosteroids may be considered in some cases, though evidence is limited. Gene therapy approaches are under active investigation in clinical trials and represent a promising future therapeutic avenue.

Common questions about Qualitative or quantitative defects of beta-sarcoglycan